Tipifarnib

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Thyroid Cancer

Conditions

Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor, Other Squamous Cell Carcinoma (SCC) With HRAS Mutant Tumor

Trial Timeline

May 13, 2015 → Dec 14, 2020

NCT ID

NCT02383927

About Tipifarnib

Tipifarnib is a phase 2 stage product being developed by Kura Oncology for Thyroid Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02383927. Target conditions include Thyroid Cancer, Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), HRAS Mutant Tumor.

What happened to similar drugs?

20 of 20 similar drugs in Thyroid Cancer were approved

Approved (20) Terminated (4) Active (0)

✅LenvatinibEisaiApproved

✅Cinacalcet HClKyowa KirinApproved

✅Growth hormone + Growth hormone treatment and pubertyEli LillyApproved

✅Paricalcitol + CalcifediolAbbVieApproved

✅Paricalcitol + Darbepoetin alfaAbbVieApproved

✅Alendronate 70mg weeklyMerckApproved

✅AMG 073AmgenApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04809233	Pre-clinical	Active	—	—	HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
NCT04865159	Phase 1	Terminated	May 6, 2021	May 2, 2023	Advanced Solid Tumor
NCT03719690	Phase 2	Completed	Mar 15, 2019	May 2, 2023	HRAS Gene Mutation
NCT02807272	Phase 2	Completed	Jan 10, 2017	Nov 30, 2020	Leukemia, Myelomonocytic, Chronic
NCT02779777	Phase 2	Terminated	Jun 1, 2016	Aug 28, 2018	Myelodysplastic Syndromes
NCT02464228	Phase 2	Completed	Feb 25, 2016	Mar 31, 2021	Relapsed or Refractory Peripheral T-Cell Lymphoma
NCT02383927	Phase 2	Completed	May 13, 2015	Dec 14, 2020	Thyroid Cancer

Competing Products

20 competing products in Thyroid Cancer

See all competitors

Product	Company	Stage	Hype Score
MBX 2109	MBX Biosciences	Phase 2	29
400 µg of MBX 2109 once-weekly by subcutaneous injection + 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection	MBX Biosciences	Phase 2	33
PCO371 + Placebo	Chugai Pharmaceutical	Phase 1	21
CS-7017 + Paclitaxel	Daiichi Sankyo	Phase 1/2	24
efatutazone + paclitaxel	Daiichi Sankyo	Phase 2	35
ASP7991 + Cinacalcet + Placebo	Astellas Pharma	Phase 2	35
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib	Eisai	Pre-clinical	26
Lenvatinib + Placebo + Lenvatinib	Eisai	Phase 3	40
Irofulven + capecitabine	Eisai	Phase 2	35
Lenvatinib + Placebo	Eisai	Phase 3	40
Lenvatinib	Eisai	Approved	43
Lenvatinib	Eisai	Pre-clinical	26
Bexarotene	Eisai	Phase 1	29
Lenvatinib + Lenvatinib matching placebo	Eisai	Phase 2	35
Lenvatinib	Eisai	Phase 2	27
LENVATINIB	Eisai	Phase 2	39
E7080 capsule	Eisai	Phase 2	35
Lenvatinib (DTC Cohort) + Lenvatinib (MTC Cohort)	Eisai	Phase 2	35
Lenvatinib 24 mg	Eisai	Phase 2	27